Related Experiment Video
Updated: Feb 1, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer
Elin Karlsson1, Cynthia Veenstra2, Jon Gårsjö1
1Department of Clinical and Experimental Medicine, Department of Oncology, Linköping University, 58185, Linköping, Sweden.
Purpose:
The protein tyrosine phosphatase, non-receptor type 2 (PTNP2) regulates receptor tyrosine kinase signalling, preventing downstream activation of intracellular pathways like the PI3K/Akt pathway. The gene encoding the protein is located on chromosome 18p11; the 18p region is commonly deleted in breast cancer. In this study, we aimed to evaluate PTPN2 protein expression in a large breast cancer cohort, its possible associations to PTPN2 gene copy loss, Akt activation, and the potential use as a clinical marker in breast cancer.
Methods:
PTPN2 protein expression was analysed by immunohistochemistry in 664 node-negative breast tumours from patients enrolled in a randomised tamoxifen trial. DNA was available for 146 patients, PTPN2 gene copy number was determined by real-time PCR.
Results:
PTPN2 gene loss was detected in 17.8% of the tumours. Low PTPN2 protein expression was associated with higher levels of nuclear-activated Akt (pAkt-n). Low PTPN2 as well as the combination variable low PTPN2/high pAkt-n could be used as predictive markers of poor tamoxifen response.
Conclusion:
PTPN2 negatively regulates Akt signalling and loss of PTPN2 protein along with increased pAkt-n is a new potential clinical marker of endocrine treatment efficacy, which may allow for further tailored patient therapies.
Insights
Loss of protein tyrosine phosphatase, non-receptor type 2 (PTNP2) in breast cancer correlates with poor tamoxifen response. Low PTNP2 and high activated Akt indicate reduced endocrine treatment efficacy, suggesting potential for tailored therapies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Protein tyrosine phosphatase, non-receptor type 2 (PTNP2) is crucial in regulating receptor tyrosine kinase signaling.
- PTNP2 normally inhibits intracellular pathways like PI3K/Akt.
- The PTNP2 gene is located on chromosome 18p11, a region frequently deleted in breast cancer.
Purpose of the Study:
- To assess PTNP2 protein expression in a large breast cancer cohort.
- To investigate associations between PTNP2 expression, gene copy loss, and Akt activation.
- To evaluate PTNP2 as a potential clinical marker in breast cancer.
Main Methods:
- Immunohistochemistry was used to analyze PTNP2 protein expression in 664 node-negative breast tumors.
- Real-time PCR determined PTNP2 gene copy number in a subset of 146 patients.
- Akt activation was assessed by measuring nuclear-activated Akt (pAkt-n).
Main Results:
- PTNP2 gene loss was observed in 17.8% of the tumors.
- Low PTNP2 protein expression correlated with increased nuclear-activated Akt (pAkt-n).
- Both low PTNP2 expression and the combination of low PTNP2/high pAkt-n predicted poor response to tamoxifen.
Conclusions:
- PTNP2 negatively regulates Akt signaling in breast cancer.
- Loss of PTNP2 protein expression, coupled with elevated pAkt-n, serves as a novel predictive marker for endocrine treatment efficacy.
- These findings may facilitate personalized patient therapies in breast cancer treatment.
Related Concept Videos
Endocrine Signaling
Treatment Resistant Cancers
What is the Endocrine System?
The Endocrine System
An Overview of the Endocrine System
The endocrine system collaborates...
Structures of the Endocrine System

